> No formal pharmacokinetic (PK) drug -drug interaction studies have been conducted with tremelimuma b. Since the primary elimination pathways of tremelimu mab are protein catabolism via reticuloendothelial system or target -mediated disposition , no metabolic drug -drug interactions are expected.  PK drug -drug interactions betwe en tremelimumab in combination with DURVALUMAB and PLATINUM -based chemotherapy were assessed in the POSEIDON study and showed no clinically meaningful PK interactions between tremelimumab, DURVALUMAB, nab -PACLITAXEL, GEMCITABINE, PEMETREXED, CARBOPLATIN or  CISPLATIN in the concomitant treatment. 
